Tuberculosis and HIV Infection: Epidemiology, Immunology, and Treatment

REFERENCES

• Annual Tuberculosis Information Summary, 1999. New York: Centers for Disease Control and Prevention; 2000.
   Google Scholar
• Robert J, Trystram D, Truffot-Pernot C, Cambau E, Jarlier V, Grosset J. Twenty-five years of tuberculosis in a French university hospital: A laboratory perspective. Int J Tuberc Lung Dis. 2000;4(6):504–512.
   PubMed Web of Science ®Google Scholar
• Bowen EF, Rice PS, Cooke NT, Whitfield RJ, Rayner CF. HIV seroprevalence by anonymous testing in patients with Mycobacterium tuberculosis and in tuberculosis contacts. Lancet. 2000;356(9240):1488–1489.
   PubMed Web of Science ®Google Scholar
• Martin V, Gayle JA, Bolea A, Castilla J. Mycobacterium tuberculosis and human immunodeficiency virus co-in-fection in intravenous drug users on admission to prison. Int J Tuberc Lung Dis. 2000;4(1):41–46.
   PubMed Web of Science ®Google Scholar
• Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: Es-timated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999;282(7):677–686.
   PubMed Web of Science ®Google Scholar
• Punnotok J, Shaffer N, Naiwatanakul T, et al. Human immunodeficiency virus-related tuberculosis and primary drug resistance in Bangkok, Thailand. Int J Tuberc Lung Dis. 2000;4(6):537–543.
   PubMed Web of Science ®Google Scholar
• DeRiemer K, Soares EC, Dias SM, Cavalcante SC. HIV testing among tuberculosis patients in the era of antiretroviral therapy: A population-based study in Brazil. Int J Tuberc Lung Dis. 2000;4(6):519–527.
   PubMed Web of Science ®Google Scholar
• Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodefi-ciency virus infection after tuberculosis. Am J Respir Crit Care Med. 1995;151(1):129–135.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Nakata K, Weiden M, Rom WN. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long termi-nal repeat. J Clin Invest 1995;95(5):2324–2331.
   PubMed Web of Science ®Google Scholar
• Nakata K, Rom WN, Honda Y, et al. Mycobacterium tu-berculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med. 1997;155(3):996–1003.
   PubMed Web of Science ®Google Scholar
• Modlin RL. Th1-Th2 paradigm: Insights from leprosy. J Invest Dermatot 1994;102 (6):828–832.
   PubMed Web of Science ®Google Scholar
• Yamamura M, Uyemura K, Deans RJ, et al. Defining pro-tective responses to pathogens: Cytokine profiles in lep-rosy lesions. Science. 1991;254(5029):277–279.
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Liu YM, Schluger NW. Local immune responses correlate with presentation and outcome in tuberculosis. Am J Respir Crit Care Med. 1998;157(3 Pt 1):729–735.
   PubMed Web of Science ®Google Scholar
• Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with inter-feron-gamma via aerosol. Lancet. 1997;349(9064):1513–1515.
   PubMed Web of Science ®Google Scholar
• Valway SE, Sanchez MP, Shinnick TF, et al. An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis. N Engl J Med. 1998; 338(10):633–639.
   PubMed Web of Science ®Google Scholar
• Manca C, Tsenova L, Barry CE, et al. Mycobacterium tuber-culosis CDC1551 induces a more vigorous host response in vivo and in vitro, but is not more virulent than other clinical isolates. J ImmunoL 1999;162(11):6740–6746.
   PubMed Web of Science ®Google Scholar
• Bishai WR, Dannenberg AM, Parrish N, et al. Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rab-bits evaluated by Lurie's pulmonary tubercle count method. Infect Immun. 1999;67(9):4931–4934.
   PubMed Web of Science ®Google Scholar
• North RJ, Ryan L, LaCource R, Mogues T, Goodrich ME. Growth rate of mycobacteria in mice as an unreliable indica-tor of mycobacterial virulence. Infect Immun. 1999;67(10):5483–5485.
   PubMed Web of Science ®Google Scholar
• Stead WW. The origin and erratic global spread of tubercu-losis. How the past explains the present and is the key to the future. Clin Chest Med. 1997;18(1):65–77.
   PubMed Web of Science ®Google Scholar
• Stead WW. Genetics and resistance to tuberculosis. Could resistance be enhanced by genetic engineering? Ann Intern Med. 1992;116(11):937–941.
   Google Scholar
• Bellamy R. Identifying genetic susceptibility factors for tu-berculosis in Africans: A combined approach using a candi-date gene study and a genome-wide screen. Clin Sci. 2000;98(3):245–250.
   PubMed Web of Science ®Google Scholar
• Bellamy R. Evidence of gene-environment interaction in de-velopment of tuberculosis. Lancet. 2000;355(9204):588–589.
   PubMed Web of Science ®Google Scholar
• Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vita-min D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: A case-control study. Lancet. 2000;355(9204):618–621.
   PubMed Web of Science ®Google Scholar
• Coronado VG, Beck-Sague CM, Hutton MD, et al. Transmis-sion of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infec-tion in an urban hospital: Epidemiologic and restriction frag-ment length polymorphism analysis. J Infect Dis. 1993;168(4)1052–1055.
   Web of Science ®Google Scholar
• Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial trans-mission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers. Ann Intern Med. 1992;117(3):191–196.
   PubMed Web of Science ®Google Scholar
• Beck-Sague C, Dooley SW, Hutton MD, et al. Hospital out-break of multidrug-resistant Mycobacterium tuberculosis in-fections. Factors in transmission to staff and HIV-infected patients. JAMA. 1992;268(10):1280–1286.
   PubMed Web of Science ®Google Scholar
• Fischl MA, Uttamchandani RB, Daikos GL, et al. An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection. Ann Intern Med. 1992;117(3):177–183.
   PubMed Web of Science ®Google Scholar
• Selwyn PA, Hertel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320(9):545–550.
   PubMed Web of Science ®Google Scholar
• Gordin FM, Matts JP, Miller C, et al. A controlled trial of isoniazid in persons with anergy and human immunodefi-ciency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1997;337(5):315–320.
   PubMed Web of Science ®Google Scholar
• Daley CL, Mugusi F, Chen LL, et al. Pulmonary complica-tions of HIV infection in Dar es Salaam, Tanzania. Role of bronchoscopy and bronchoalveolar lavage. Am J Respir Crit Care Med. 1996;154(1):105–110.
   PubMed Web of Science ®Google Scholar
• Asimos AW, Ehrhardt J. Radiographic presentation of pul-monary tuberculosis in severely immunosuppressed HIV-seropositive patients. Am J Emerg Med. 1996;14(4):359–363.
   PubMed Web of Science ®Google Scholar
• Law KF, Jagirdar J, Weiden MD, Bodkin M, Rom WN. Tuber-culosis in HIV-positive patients: Cellular response and im-mune activation in the lung. Am J Respir Crit Care Med. 1996;153(4 Pt 1):1377–1384.
   PubMed Web of Science ®Google Scholar
• Law K, Weiden M, Harkin T, Tchou-Wong K, Chi C, Rom WN. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;153(2):799–804.
   PubMed Web of Science ®Google Scholar
• Werneck-Barroso E, Bonecini-de-Almeida MD, Vieira MA, et al. Preferential recruitment of phagocytes into the lung of patients with advanced acquired immunodeficiency syn-drome and tuberculosis. Respir Med. 2000;94(1):64–70.
   PubMed Web of Science ®Google Scholar
• Nowakowski M, Chan SP, Steiner P, Chice S, Durkin HG. Different distributions of lung and blood lymphocyte subsets in pediatric AIDS or tuberculosis. Ann Clin Lab Sci. 1992;22(6):377–384.
   PubMed Web of Science ®Google Scholar
• Nowakowski M, Clarke LM, Amaro R, Pellegrino MG, Sierra MF, Steiner P. Characterization of cells, immunoglobulins, and immune complexes present in the bronchoalveolar lay-age of pediatric AIDS patients. Reg ImmunoL 1992;4(1):34–40.
   PubMedGoogle Scholar
• Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158(1):157–161.
   PubMed Web of Science ®Google Scholar
• Whalen CC, Nsubuga P, Okwera A, et al. Impact of pulmo-nary tuberculosis on survival of HIV-infected adults: A pro-spective epidemiologic study in Uganda. AIDS. 2000;14(9)1 219–1228.
   Web of Science ®Google Scholar
• Targeted tuberculin testing and treatment of latent tubercu-losis infection. Am J Respir Crit Care Med. 2000;161(4 Pt 2):5221–247.
   Web of Science ®Google Scholar
• CDC. Anergy skin testing and preventive therapy for HIV-infected persons: Revised recommendations. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 1997;46(RR-15):1–10.
   PubMedGoogle Scholar
• Daley CL, Hahn JA, Moss AR, Hopewell PC, Schecter GF. Incidence of tuberculosis in injection drug users in San Francisco: Impact of anergy. Am J Respir Crit Care Med. 1998;157(1):19–22.
   PubMed Web of Science ®Google Scholar
• Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration. N Engl J Med. 1997; 337(12):801–808.
   PubMed Web of Science ®Google Scholar
• Control and prevention of tuberculosis in the United King-dom: Code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax. 2000;55(11):887–901.
   PubMed Web of Science ®Google Scholar
• Bock NN, Metzger BS, Tapia JR, Blumberg HM. A tuberculin screening and isoniazid preventive therapy program in an inner-city population. Am J Respir Crit Care Med. 1999;159(1):295–300.
   PubMed Web of Science ®Google Scholar
• Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thai-land. AIDS. 1997;11(1)1 07–112.
   Web of Science ®Google Scholar
• Camins BC, Bock N, Watkins DL, Blumberg HM. Accep-tance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion. JAMA. 1996;275(13)1 013–1015.
   Web of Science ®Google Scholar
• Codecasa LR, Besozzi G. Acceptance of isoniazid preven-tive treatment by close contacts of tuberculosis cases: A 692-subject Italian study. Int J Tuberc Lung Dis. 1998;2(3):208–212.
   PubMed Web of Science ®Google Scholar
• Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazi-namide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Pre-vention Study Group. JAMA. 2000;283(11):1445–1450.
   PubMed Web of Science ®Google Scholar
• Halsey NA, Coberly JS, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for pre-vention of tuberculosis in HIV-1 infection. Lancet. 1998;351(9105):786–792.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with hu-man immunodeficiency virus: Principles of therapy and re-vised recommendations. MMWR Moth Mortal Wkly Rep. 1998;47(RR-20):1–58.
   PubMedGoogle Scholar
• Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuber-culosis. Clin Infect Dis. 2000;30(5):779–783.
   PubMed Web of Science ®Google Scholar
• Park MM, Davis AL, Schluger NW, Cohen H, Rom WN. Outcome of MDR-TB patients, 1983-1993. Prolonged sur-vival with appropriate therapy. Am J Respir Cnt Care Med. 1996;153(1):317–324.
   PubMed Web of Science ®Google Scholar
• Boiselle PM, Tocino I, Hooley RJ, et al. Chest radiograph interpretation of Pneumocystis carinii pneumonia, bacterial pneumonia, and pulmonary tuberculosis in HIV-positive pa-tients: Accuracy, distinguishing features, and mimics. J Thorac Imaging. 1997 ; 12 (1):47–53.
   PubMed Web of Science ®Google Scholar
• Flora GS, Modilevsky T, Antoniskis D, Barnes PF. Undiag-nosed tuberculosis in patients with human immunodefi-ciency virus infection. Chest. 1990;98(5):1056–1059.
   PubMed Web of Science ®Google Scholar
• Kramer F, Modilevsky T, Waliany AR, Leedom JM, Barnes PF. Delayed diagnosis of tuberculosis in patients with hu-man immunodeficiency virus infection [see comments]. Am J Med. 1990;89(4):451–456.
   PubMed Web of Science ®Google Scholar
• Shafer RW, Kim DS, Weiss JP, Quale JM. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine. 1991;70(6):384–397.
   PubMed Web of Science ®Google Scholar
• Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculo-sis to CD4 cell counts in patients with human immunodefi-ciency virus infection. Am Rev Respir Dis. 1993;148(5):1292–1297.
   PubMed Web of Science ®Google Scholar
• Jones BE, Oo MM, Taikwel EK, et al. CD4 cell counts in human immunodeficiency virus-negative patients with tu-berculosis. Clin Infect Dis. 1997;24(5):988–991.
   PubMed Web of Science ®Google Scholar
• Pitchenik AE, Rubinson HA. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. Am Rev Respir Dis. 1985; 131 (3):393–396.
   PubMed Web of Science ®Google Scholar
• Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1881–1884.
   PubMed Web of Science ®Google Scholar
• Sandman L, Schluger NW, Davidow AL, Bonk S. Risk fac-tors for rifampin-monoresistant tuberculosis: A case-control study. Am J Respir Crit Care Med. 1999;159(2):468–472.
   PubMed Web of Science ®Google Scholar
• Schluger N, Ciotoli C, Cohen D, Johnson H, Rom WN. Comprehensive tuberculosis control for patients at high risk for noncompliance. Am J Respir Crit Care Med. 1995;151(5):1486–1490.
   PubMed Web of Science ®Google Scholar
• Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consen-sus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA. 1998;279(12):943–948.
   PubMed Web of Science ®Google Scholar
• Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274(12):945–951.
   PubMed Web of Science ®Google Scholar
• Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159(3):733–740.
   PubMed Web of Science ®Google Scholar
• Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D. Twice-weekly, directly observed treatment for HIV-in-fected and uninfected tuberculosis patients: Cohort study in rural South Africa. AIDS. 1999;13(7):811–817.
   PubMed Web of Science ®Google Scholar
• Connolly C, Reid A, Davies G, Sturm W, McAdam KP, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS. 1999; 13(12):1543–1547.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Perlman DC, Matts JP, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Pro-grams for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis. 1998;26(5):1148–1158.
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculo-sis drug concentrations in patients with AIDS. Ann Pharmacother. 1996;30(9):919–925.
   PubMed Web of Science ®Google Scholar
• Controlled trial of 6-month and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazina-mide for pulmonary tuberculosis in Hong Kong. The results up to 30 months. Am Rev Respir Dis. 1977;115(5):727–735.
   PubMed Web of Science ®Google Scholar
• Dutt AK, Stead WW. Chemotherapy of tuberculosis for the 1980s. Prim Care. 1980;7(3):513–527.
   PubMed Web of Science ®Google Scholar
• Burman WJ, Gallicano K, Peloquin C. Therapeutic implica-tions of drug interactions in the treatment of human immu-nodeficiency virus-related tuberculosis. Clin Infect Dis. 1999;28(3):419–429.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Morb Mortal Wkly Rep. 1998;47(RR-5):43–82.
   Google Scholar
• Munsiff S, Fujiwara P. Treatment of tuberculosis in patients taking antivirals. The AIDS Reader 2000;10(2)1 02–108.
   Google Scholar
• Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329(11):784–791.
   PubMed Web of Science ®Google Scholar